<DOC>
	<DOCNO>NCT02654678</DOCNO>
	<brief_summary>Paediatric long-term safety follow-up clinical trial maximum 100 child heart failure due dilate cardiomyopathy congenital heart disease , 1 day less 12 year age recruitment precede short-term pharmacokinetic ( PK ) /pharmacodynamic ( PD ) trial . Pharmacodynamic measurement renal monitoring child 1 , 4 , 7 10 month follow-up ; addition PK assessment well acceptability palatability assessment child still enalapril Orodispersible Minitablet ( ODMT ) treatment .</brief_summary>
	<brief_title>Follow-up Safety Trial Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets Enalapril</brief_title>
	<detailed_description>This clinical trial one three clinical trial European Commission ( FP7 ) -funded `` LENA '' ( Labeling Enalapril Neonates Adolescents ) project : 50 child heart failure due dilate cardiomyopathy ( LENA-Work Package ( WP ) 08 Trial ) 50 child heart failure due congenital heart disease ( LENA-WP09 Trial ) get treat optimal dose enalapril ODMTs 8 week thorough , individualise titration get invite join 10 month Safety Follow-up Study ( LENA-WP10 Trial ) . Reliable data long-term safety enalapril paediatric patient currently available . By conduct long-term Safety Follow-up Trial child receive still receive enalapril Orodispersible Minitablets end 8-weeks PK/PD LENA-Work Package ( WP ) 08 ( child heart failure due dilate cardiomyopathy ) LENA-WP09 ( child heart failure due congenital heart disease ) Trials use sensitive highly specific assay methodology , possible add generation reliable PK PD data whole paediatric age range birth 12 year . In addition , follow-up study allow systematically collect follow-up information 10 month , total 12 month , paediatric patient long-term enalapril ODMT treatment paediatric patient receive least 3 day ODMT treatment stop reason . The End-of-study Visit WP08 WP09 Trials also First Visit Follow-up Study . Further Visits occur 1 month , 4 month , 7 month 10 month . At Visit blood pressure renal monitoring well pharmacodynamic parameter adverse event assess . In child ongoing enalapril ODMT treatment , single PK sample well acceptability palatability assessment make Visit .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>Patients WP08 WP09 Trials treat enalapril Orodispersible Minitablets still ODMT treatment . Patients WP08 WP09 Trials treat least 3 day enalapril Orodispersible Minitablets longer ODMT treatment . Written inform consent parent ( ) /legal representative provide write informed consent participation long term followup study assent patient accord national legislation far achievable child . Patients enrol treated WP08 WP09 Trials fulfil respective exclusion criterion protocols . As aim Followup Study observe safety patient expose enalapril ODMT treatment , additional exclusion criterion define protocol . However , adapt health situation patient , investigator decide whether planned study activity perform .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>